On 28 April 2026, the reformed UK clinical trials regulatory regime came into force under The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (SI 2025/538), which amends the Medicines for Human Use (Clinical Trials) Regulations 2004. Jointly developed by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA), it is described by both bodies as the largest package of reforms to UK clinical trial regulation in over two decades. This page summarizes what changed, why, and what it means in practice for sponsors, investigators, and research administrators running clinical trials of investigational medicinal products (CTIMPs) in the UK.
What changed and when
SI 2025/538 was made in April 2025 and, after a roughly 12-month implementation period intended to give sponsors, sites, and RECs time to adapt, took legal effect on 28 April 2026. It amends, rather than replaces, the original 2004 Regulations (themselves the UK’s implementation of the former EU Clinical Trials Directive, 2001/20/EC) — so the underlying legal instrument is the same one research administrators have worked under for two decades, now substantially rewritten in its approval, oversight, and transparency provisions.
Why the reform happened
The reform followed several years of UK government and regulator commitment to make the UK more competitive as a location for clinical trials, following a 2021 review of UK commercial clinical trials (the O’Shaughnessy review) that flagged slow, duplicative approval processes as a competitive disadvantage. The stated aims of the reform are faster, more proportionate regulatory review without lowering participant safety or scientific standards, and — for the first time under UK domestic law — a binding public-transparency obligation for trial registration and results reporting.
Key changes for sponsors and investigators
Risk-proportionate (risk-adapted) approach to review
The reformed regime formally builds a risk-proportionate approach into how applications and modifications are assessed, so that lower-risk trials — for example, trials of medicines already well characterized in humans, or trials with minimal added intervention risk relative to standard care — can move through review and start faster, while trials that raise more novel safety questions continue to receive fuller scrutiny. This mirrors the risk-based, quality-by-design philosophy already embedded in ICH E6(R3)‘s approach to Good Clinical Practice, applied here at the level of national regulatory review rather than trial conduct.
Combined MHRA/REC review
Applications are assessed through a single combined process in which the MHRA (safety and quality) and the relevant Research Ethics Committee, or REC (ethics) run their assessments together rather than sequentially, with a single overall timeline and the ability for either body to request modifications where needed. The HRA reports that combined review timelines have fallen substantially under this model — averaging around 41 days by early 2026, roughly half the pre-reform combined-review duration, and beating the government’s own 150-day end-to-end target for trial set-up. For general background on how ethics and regulatory review bodies interact, see CASRAI’s guide to the IRB/REC approval process.
Notifiable trials and faster first-in-human review
A new fast-track “notifiable trials” route allows certain lower-risk trials and lower-risk modifications to proceed on a shortened timeline. The reform also introduces measures intended to speed the assessment of first-in-human trials specifically, including provision for greater use of validated overseas safety data and computer modelling/simulation evidence where it meets UK evidentiary standards, alongside the traditional nonclinical package.
Route B substantial modifications
A “Route B” pathway for eligible substantial modifications — piloted from October 2025 to March 2026 ahead of the regulations taking effect — became a legally mandated option from 28 April 2026. Under Route B, an eligible modification is treated as approved automatically unless the MHRA or REC raises a concern within a fixed 14-day window; during the pilot, eligible modifications were processed in an average of around 7 calendar days. This is a significant change from the pre-reform default, under which most substantial amendments required active regulatory sign-off before implementation regardless of how routine the change was.
Mandatory registration and results transparency
For the first time under UK law, sponsors of CTIMPs are legally required to: register the trial on a public registry before it starts recruiting; publish a summary of trial results within 12 months of the trial’s conclusion; and offer participants a summary of results in lay language. Previously, registration and results-reporting expectations in the UK rested on funder and publisher policy (for example, ICH GCP expectations, funder mandates, and journal/ICMJE registration requirements) rather than a standalone UK statutory duty. This closes a gap that transparency advocates — including the AllTrials campaign and academic audits of registry compliance — had raised for years.
What this means in practice
- Sponsors should expect a genuinely faster route to first patient enrolled for lower-risk protocols, but should build the new registration and results-publication obligations into trial master file planning and closeout timelines from the outset, not as an afterthought — these are now statutory duties, not funder-policy best practice.
- Investigators and sites working with sponsors on Route B-eligible modifications should understand that “no objection within 14 days” now functions as approval — internal site processes for tracking and implementing amendments need to be able to move at that pace rather than assuming a formal written approval will always arrive first.
- Research administrators and regulatory affairs staff should treat the reform as changing process and timeline, not the substance of what constitutes an ethical, well-conducted trial — the core Good Clinical Practice obligations under ICH E6(R3) and the documentation expected in the Investigational Medicinal Product Dossier (IMPD) for the investigational medicinal product itself are unchanged by this reform.
- Trials already in progress before 28 April 2026 are subject to transitional arrangements published by the MHRA and HRA rather than an immediate, universal switch-over — sponsors of ongoing trials should check current MHRA/HRA guidance for their specific trial’s transition status rather than assume the old or new regime applies by default.
Frequently asked questions
What is the legal instrument behind the reform?
The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (SI 2025/538), which amends the Medicines for Human Use (Clinical Trials) Regulations 2004. The text is publicly available on legislation.gov.uk.
Does the reform apply across the whole UK?
Yes — the amending regulations extend to England, Wales, Scotland, and Northern Ireland.
Does this reform replace ICH GCP or ICH E6(R3) obligations?
No. The reform changes how trial applications and modifications are reviewed and approved in the UK, and adds new statutory transparency duties. It does not replace or lower the underlying Good Clinical Practice standard that governs how a trial is actually conducted, which continues to be set by ICH E6(R3).
What happens if a sponsor doesn’t register a trial or publish results?
Registration before recruitment starts and publication of a results summary within 12 months of trial conclusion are now legal requirements under the amended regulations, not voluntary good practice — sponsors should treat them as compliance obligations with the same seriousness as any other regulatory duty under the 2004 Regulations as amended. For the specific enforcement mechanisms, consult current MHRA/HRA guidance directly, as this page summarizes the regulatory change rather than restating enforcement procedure in full.
This page reflects the regulatory framework as it stood in mid-2026, drawn from MHRA, HRA, and legislation.gov.uk sources. MHRA and HRA guidance continues to be refined as the reformed regime beds in — always check current MHRA/HRA guidance for a specific trial’s requirements rather than relying solely on this summary.
